Seriphadine — Project Overview

Design · Synthesis · Effects — quick access to the full paper

The rational design of psychoactive compounds has historically prioritized either therapeutic efficacy or recreational appeal-rarely both. This work presents the synthesis and pharmacological profile of Seriphadine, a novel molecular architecture engineered to occupy the intersection of clinical utility and hedonic experience. Through strategic incorporation of carbamate, dihydroisoquinoline, and pyrrolidinone moieties, the compound exhibits multi-target activity: positive allosteric modulation at GABA-A receptors, mild NMDA antagonism, 5-HT 2𝐴 partial agonism, and sigma-1 receptor engagement. Structure-activity relationship modeling predicts a dose-dependent progression from anxiolytic warmth (2-5 mg) to dissociative euphoria with oneirogenic clarity (20+ mg), with minimal D 2 binding mitigating dysphoric or psychotomimetic liability. A five-step convergent synthesis yields the target compound in 65-72% overall yield with ≥98% purity. This work demonstrates that deliberate polypharmacology, when executed with mechanistic precision, can produce molecules tailored for both relief and recreation.